Sign up to save your podcasts
Or
Share NewLimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to improve cell function and thus aim to extend longevity
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NewLimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to improve cell function and thus aim to extend longevity
Co-Founder & President Jacob Kimmel and Head of Operations Cathy O'Hare describe the scientific approach and how it benefits from the crossroads of genomics and machine learning. Plus, which indications the company plans to start out in clinically.
View all episodes
By BiotechTV
4.3
77 ratings
Co-Founder & President Jacob Kimmel and Head of Operations Cathy O'Hare describe the scientific approach and how it benefits from the crossroads of genomics and machine learning. Plus, which indications the company plans to start out in clinically.
More shows like BiotechTV - News
View all
WSJ What’s News
4,419 Listeners
The a16z Show
1,109 Listeners
The Meb Faber Show - Better Investing
950 Listeners
The Daily
113,515 Listeners
The Readout Loud
336 Listeners
The Intelligence from The Economist
2,577 Listeners
The Prof G Pod with Scott Galloway
5,658 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,242 Listeners
Business Of Biotech
87 Listeners
BioCentury This Week
35 Listeners
Biotech Hangout
21 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
470 Listeners
Prof G Markets
1,478 Listeners
The BioCentury Show
12 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
3 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners